文献速递临床试验与 GCP

肘关节置换与切开复位内固定治疗老年肱骨远端C2/C3骨折的随机对照试验

Elbow hemiarthroplasty versus open reduction and internal fixation for AO/OTA type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above: a randomized controlled trial.
PubMed 文献 · Trials · 2020-06-08

该研究是一项研究者发起的非盲随机对照试验方案,比较肘关节置换(EHA)与切开复位内固定(ORIF)在50岁及以上AO/OTA 13 C2和C3型肱骨远端骨折患者中的疗效。

要点

  • 针对50岁及以上AO/OTA 13 C2/C3型肱骨远端骨折患者比较EHA与ORIF。
  • 假设EHA并发症更少且功能结局优于ORIF,并可避免TEA铰链相关机械并发症。

核心结论

  • 研究旨在探讨50岁及以上患者AO/OTA 13 C2和C3型肱骨远端骨折的最佳治疗选择。
  • 假设EHA相比ORIF并发症更少、功能结局更优,且可避免TEA铰链相关机械并发症。

研究设计与样本

  • 研究者发起的非盲随机对照试验方案,比较EHA与ORIF。
  • 主要结局为牛津肘关节评分(OES),随访至术后10年。

关键数值与推荐

  • 纳入标准:年龄≥50岁,AO/OTA 13 C2和C3型肱骨远端骨折。
  • 主要结局:牛津肘关节评分(OES)。
  • 次要结局:Mayo肘关节性能评分(MEPS)、疼痛严重程度评分(VAS)、活动度、患者满意度。
  • 记录再手术、并发症和病假时长。
  • 随访时间点:术后、3个月、1年、2年、5年和10年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraarticular distal humeral fractures of AO/OTA type 13 C2 and C3 pose a surgical challenge despite the evolution of surgical implants and techniques. Open reduction and internal fixation (ORIF) is often preferred as the first choice of treatment, but the results vary and are sometimes disappointing. Total elbow arthroplasty (TEA) has been widely used for fractures that are not amenable to ORIF in elderly patients, but the mechanical complications remain a challenge, especially in active patients. Elbow hemiarthroplasty (EHA) provides a modern alternative that might avoid the mechanical complications and weight bearing restrictions related to the linked articulation in semi-constrained TEA. No studies have compared the results of EHA to that of ORIF, but case series have reported promising results. METHODS/DESIGN: This is a study protocol describing an investigator-initiated, non-blinded randomized controlled trial comparing the outcome of EHA with ORIF for AO/OTA type 13 C2 and C3 fractures of the distal humerus in patients who are 50 years or older. Forty-four patients with AO/OTA type 13 C2 and C3 fractures of distal humerus will be randomized to either EHA or ORIF. The Oxford Elbow Score (OES) will be used as primary outcome. Mayo Elbow Performance Score (MEPS), pain severity score (VAS), range of motion, and patient satisfaction will be used as secondary outcomes. Reoperations, complications, and the length of sick leave will be recorded. The patients will be examined after the operation and at 3 months and 1, 2, 5, and 10 years. DISCUSSION: The main objective of this study is to investigate the best treatment option for AO/OTA type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above. We hypothesize that EHA results in fewer complications and superior functional outcome compared with ORIF and that the mechanical complications related to the linked articulation of TEA can be avoided. TRIAL REGISTRATION: ClinicalTrials.gov, PRS, NCT04163172. Registered November 13, 2019. https://clinicaltrials.gov/ct2/results?cond=&term=evori&cntry=&state=&city=&dist= (Table 2). The protocol has been approved by The Scientific Ethics Committee of the Capital Region of Denmark (Jr. no.: H- 19,035,590). The processing of personal data has been approved by the Danish Data Protection Agency (Jr. no. P-2019-246). Inclusion started on February 1, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Al-Hamdani A, Rasmussen JV, Holtz K, et al. Elbow hemiarthroplasty versus open reduction and internal fixation for AO/OTA type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above: a randomized controlled trial. Trials. 2020. PMID: 32513252. doi:10.1186/s13063-020-04418-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。